ArticleBMC plant biology2025
Plant growth-promoting Nocardia JTT02 enhances Biomass, glucosinolate metabolism, and bioactive potential of three Lepidium sativum cultivars.
Article in BMC plant biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phytochemical insights and pharmacological advances of Lepidium sativum L. (garden cress): bridging traditional medicine and evidence-based therapeutics.Journal, genetic engineering & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lepidium sativum (garden cress) is a nutritionally valuable plant rich in proteins, dietary fiber, omega-3 fatty acids, vitamins, and essential phytochemicals, and has a history of use in traditional medicine. This study investigated the potential of a novel endophytic actinobacterium, Nocardia JTT02, isolated from Tribulus terrestris (Jazan region, KSA) to enhance the biofortification of three L. sativum cultivars (Haraz, Rajab, and Khider). Nocardia JTT02, a potent plant growth-promoting (PGP) endophyte, significantly improved the biomass and photosynthetic activity (including Rubisco) in all cultivars. This enhancement is attributed to JTT02's production of phytohormones like auxin and gibberellin. Moreover, the improved photosynthesis by JTT02 treatment resulted in elevated levels of primary metabolites, including organic acids, fatty acid and essential amino acids, which serve as precursors for glucosinolates and phenolics. Correspondingly, individuals glucosinoaltes (e.g., glucotropaeolin, benzaldehyde, benzyl cyanide, and benzyl thiocyanate) and total glucosinolate content were elevated. This also correlated with the bacteria's ability to produce amino acids, which are precursors for glucosinolate metabolism. Along with these increases, overall myrosinase activity and concentrations of glucosinolate hydrolysis products also significantly increased. Furthermore, the accumulation of antioxidant metabolites, including phenolic acids and flavonoids, was enhanced by JTT02, leading to increased antioxidant capacity as determined by FRAP, ABTS, and DPPH assays. The JTT02 boosted the accumulation of bioactive metabolites also increased antibacterial activity against various pathogen. These results suggest that Nocardia JTT02 is promising as a biofertilizer for improving the growth, nutritional value, and disease resistance of L. sativum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.